The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...
Boosting Bacteroides vulgatus in diabetic mice increased GLP-1 secretion, improving blood sugar control and reducing sugar ...
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback